Rapamycin
An mTOR inhibitor studied in longevity research, considered under close clinical oversight.
- Explored in longevity-focused care on the strength of animal lifespan data
- mTOR inhibition — shifting cells from growth toward maintenance and autophagy
Not an approved indication. Any use for healthy aging is off-label, and no completed human trial has shown rapamycin extends lifespan or healthspan.
Indicative price · confirmed after eligibility · prescription treatment
What rapamycin is
Rapamycin occupies an unusual position. It is one of the very few compounds with reproducible evidence for extending lifespan in mammals — and it is also a genuine immunosuppressant with a real side-effect profile, approved for entirely different purposes than the one people come to us asking about.
Both of those things are true at once, and holding them together is the whole job. Rapamycin is not a supplement with an interesting mechanism. It is a serious medication being used off-label on the strength of animal data and early human work, and it is only appropriate for people who understand that and will commit to being monitored.
Rapamycin — also called sirolimus — was isolated from a soil bacterium found on Easter Island, which is where the name comes from (Rapa Nui). It is FDA-approved for preventing organ rejection after kidney transplant and for treating a rare lung condition, lymphangioleiomyomatosis. Neither of those is why it appears on this page. It works by inhibiting mTOR, a cellular signaling pathway that acts roughly as a nutrient sensor. When mTOR is active, cells prioritize growth and building; when it is inhibited, they shift toward maintenance and cellular clean-up, including autophagy — the process by which cells clear out damaged components. That trade-off between growth and maintenance is one of the most consistent themes in aging biology, and it is why mTOR inhibition became interesting to researchers studying lifespan rather than transplant medicine.
How it works here
Every plan follows one path. Each step feeds the next. See the NAD+ Therapy approach.
- 01
Measure
We baseline your labs, history, and goals.
- 02
Plan
A clinician decides whether this fits — and what else might serve you.
- 03
Act
If appropriate, you start with clear guidance and high-touch support.
- 04
Track
We monitor how you respond on a defined cadence.
- 05
Adjust
Protocols are refined over time. Guided care, not a kit in the mail.
How rapamycin compares to other longevity options
The three prescription options most often discussed in longevity-focused care, compared on what actually separates them.
| Rapamycin | Metformin | NAD+ Injection | |
|---|---|---|---|
| Mechanism | mTOR inhibition — shifts cells from growth toward maintenance and autophagy | Improves insulin sensitivity; AMPK activation | Supports NAD+ availability for cellular energy metabolism |
| Animal lifespan evidence | Strong and reproduced across independent labs, including when started mid-life | Mixed | Limited |
| Human evidence | Early — no completed lifespan or healthspan trial | Long everyday safety record; longevity endpoints unproven | Early |
| FDA status | Approved for transplant and a rare lung condition; longevity use is off-label | Approved for type 2 diabetes; longevity use is off-label | Compounded |
| Risk profile | Highest of the three — immunosuppression, impaired wound healing, lipid and glucose effects | Low, well characterized | Low |
| Drug interaction load | High — CYP3A4, including grapefruit | Low | Low |
| Monitoring required | Substantial and non-negotiable | Routine | Light |
| Ruled out by | Active infection, upcoming surgery, pregnancy, unwillingness to be monitored | Significant kidney impairment | Rarely ruled out |
| Best suited to | People who want the strongest animal evidence and accept real risk and real monitoring | People wanting a low-risk, metabolically-anchored option | People starting out in longevity-focused care |
Scroll the table sideways to compare →
The honest summary: rapamycin has the best animal data and the most risk. Metformin has the least risk and the weakest longevity signal. Neither is a substitute for sleep, training and body composition, and both are conversations for after those are handled.
Who this isn't right for
Rapamycin suppresses immune function. That is its approved mechanism of action, not a side effect, and it drives most of the reasons someone shouldn't take it.
If you have an active infection, or you're prone to recurrent infections, rapamycin is not appropriate. Reduced immune surveillance means infections can establish more easily and resolve more slowly.
If you have surgery coming up. Rapamycin impairs wound healing. Any planned procedure — including dental work of any significance — needs to be discussed in advance, because timing around it matters.
If you're due vaccinations, particularly live vaccines, this needs planning. Immunosuppression affects both the safety of live vaccines and the response you mount to any vaccine.
If you're pregnant, planning pregnancy, or breastfeeding.
If you have poorly controlled lipids or blood sugar. Rapamycin can raise triglycerides and cholesterol, and can affect glucose handling and insulin sensitivity. Existing metabolic problems make it a harder case.
If you have significant kidney or liver impairment, or a history of certain lung conditions.
If you won't commit to monitoring. This is the one that disqualifies most people in practice. Rapamycin without regular labs isn't a longevity strategy; it's an unsupervised experiment with an immunosuppressant.
Interactions — a bigger issue than most people expect
Rapamycin is metabolized through the CYP3A4 pathway, which is one of the busiest drug-metabolism routes in the body. That means a long list of common medications can raise or lower its levels significantly — including some antibiotics, antifungals, blood pressure medications, statins, seizure medications and antidepressants.
Grapefruit and grapefruit juice affect the same pathway and are worth mentioning specifically, because people don't think of food as an interaction.
For a patient in their fifties or sixties on two or three regular medications, this is not a footnote — it is a central part of whether rapamycin is workable at all. Bring your complete medication and supplement list to your evaluation, including anything you take occasionally.
What monitoring actually involves
Most pages selling rapamycin mention monitoring in passing. It is worth being concrete, because this is the part that determines whether the whole thing is responsible.
A baseline before starting: lab work covering lipids, glucose and HbA1c, complete blood count, and kidney and liver function, alongside a full medication review and a history that specifically covers infections, upcoming procedures and vaccination status.
Then follow-up on a defined cadence — not “if something feels wrong,” because the changes rapamycin causes most often are the kind you don't feel. Rising triglycerides and drifting glucose are silent. So is a falling white cell count.
And a standing agreement about what pauses or stops it: an infection, a planned surgery, a lab result moving the wrong way. Knowing in advance what would make you stop is a sign of a real protocol.
Delivery
An oral medication, used strictly as directed with clinical monitoring. How it is scheduled is a clinical decision and differs meaningfully from how rapamycin is used in transplant medicine. Your clinician sets and adjusts that with you, informed by your labs and how you respond.
Is it right for you?
Rapamycin comes up most often among adults exploring longevity-focused care who have already handled the foundations — sleep, training, nutrition, body composition, and any hormonal or metabolic issue that is actually driving how they feel — and who want to discuss what sits above that layer. It is a poor first move. If you're tired, or your body composition has shifted, or your recovery has slowed, the productive first step is finding out why. Most of the time there is a more direct answer than an immunosuppressant, and measuring first is how you find it. For people exploring the same territory with a lower risk profile, NAD+ therapy, metformin and methylene blue are the more common starting conversations.
Often considered alongside
NAD+ Injection
CompoundedA coenzyme central to cellular energy, explored to support energy and recovery in midlife.
View treatmentMethylene Blue
CompoundedA compound explored at low doses for mitochondrial and cognitive support.
View treatmentMetformin
A long-established oral medication that supports insulin sensitivity and metabolic health.
View treatmentProducts marked Compounded are prepared by a licensed compounding pharmacy under a prescription written for you. Compounded medications are not FDA-approved and are not equivalent to or interchangeable with any branded product.
What the longevity evidence actually shows
Precision matters here, because this is routinely overstated. In animals the evidence is real and reproducible: rapamycin has extended lifespan in mice across multiple independent laboratories, including in studies where it was started in already-middle-aged animals. Reproducibility across labs is a meaningfully high bar, and rapamycin clears it — very few interventions do. In humans the evidence is early. There is no completed trial demonstrating that rapamycin extends human lifespan or healthspan. What exists is smaller work on specific endpoints, ongoing studies, and a growing off-label practice that is generating experience rather than proof. Anyone telling you the human question is settled is describing a hope, not a result. Our position: the animal data is strong enough that rapamycin is a legitimate thing to discuss for some people. It is not strong enough to justify treating it casually, and the gap between mouse lifespan and human healthspan is exactly where honesty is required.
References
Government and professional-society sources consulted for this page.
- Sirolimus — MedlinePlus (U.S. National Library of Medicine)
- Understanding Unapproved Use of Approved Drugs “Off Label” — U.S. Food and Drug Administration
Frequently asked questions
No. Rapamycin is FDA-approved for preventing kidney transplant rejection and for a rare lung condition. Any use for healthy aging is off-label, is not FDA-approved for that purpose, and is considered only under clinical oversight for eligible patients.
In mice, yes — reproducibly, across independent laboratories, including when started in middle age. In humans, that hasn't been demonstrated. The animal evidence is what makes it worth discussing; the absence of human evidence is what makes realistic expectations essential.
The main one is immunosuppression, which raises infection risk and impairs wound healing. Rapamycin can also raise cholesterol and triglycerides, affect blood sugar handling, and cause mouth ulcers. It interacts with a wide range of common medications. It isn't right for everyone, and eligibility screening is genuinely a screen.
This needs to be planned rather than improvised, because rapamycin impairs wound healing. Tell your clinician about any procedure well in advance — including significant dental work.
Sometimes, but the interaction list is long because rapamycin uses the CYP3A4 pathway. Some antibiotics, antifungals, statins and blood pressure medications are affected, as is grapefruit. Bring a complete list, including occasional medications and supplements.
Chiefly in scheduling and intent. Transplant medicine aims for sustained immunosuppression; the longevity discussion is oriented around intermittent exposure intended to avoid that. The specifics are a clinical decision, and the difference is one reason transplant-derived side-effect statistics don't transfer cleanly.
A baseline and then regular follow-up covering lipids, glucose and HbA1c, blood counts, and kidney and liver function. Monitoring isn't a formality here — most of what rapamycin changes doesn't produce symptoms until it's well advanced.
Different mechanisms, different evidence bases and different risk profiles. Metformin has a longer everyday safety record and a milder profile; rapamycin has stronger animal lifespan data and more risk. Which — if either — fits depends on your labs, history and how you weigh those.
See if Rapamycin fits your plan
The right plan begins with knowing where you are. Start with a short eligibility check and a baseline — and we'll tell you, honestly, what fits.
We measure first. Then we act.
ACT 2 Health provides clinician-led care. Treatments described are available only to eligible patients following clinical evaluation and within applicable regulations. This page is educational and is not medical advice. Individual results vary.